• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Clin Med . Impact of Corticosteroid Administration within 7 Days of the Hospitalization for Influenza Pneumonia with Respiratory Failure: A Prope

tetano

Editor, Senior Moderator
J Clin Med


. 2021 Jan 31;10(3):494.
doi: 10.3390/jcm10030494.
Impact of Corticosteroid Administration within 7 Days of the Hospitalization for Influenza Pneumonia with Respiratory Failure: A Propensity Score Analysis Using a Nationwide Administrative Database


Daisuke Okuno[SUP] 1 [/SUP], Takashi Kido[SUP] 1 [/SUP], Keiji Muramatsu[SUP] 2 [/SUP], Kei Tokutsu[SUP] 2 [/SUP], Sakiko Moriyama[SUP] 1 [/SUP], Takuto Miyamura[SUP] 1 [/SUP], Atsuko Hara[SUP] 1 [/SUP], Hiroshi Ishimoto[SUP] 1 [/SUP], Hiroyuki Yamaguchi[SUP] 1 [/SUP], Taiga Miyazaki[SUP] 3 [/SUP], Noriho Sakamoto[SUP] 1 [/SUP], Yasushi Obase[SUP] 1 [/SUP], Yuji Ishimatsu[SUP] 4 [/SUP], Yoshihisa Fujino[SUP] 5 [/SUP], Kazuhiro Yatera[SUP] 6 [/SUP], Shinya Matsuda[SUP] 2 [/SUP], Hiroshi Mukae[SUP] 1 [/SUP]



Affiliations

Abstract

Influenza pneumonia, which causes acute respiratory distress syndrome and multiple organ failure, has no established management protocol. Recently, corticosteroid therapy was used to treat coronavirus disease 2019 with respiratory failure; however, its effectiveness as a treatment for influenza pneumonia remains controversial. To investigate the impact of corticosteroid therapy for the early phase of severe influenza pneumonia, we compared influenza pneumonia patients with respiratory failure treated with or without corticosteroids within 7 days after hospital admission using a Japanese nationwide administrative database. The primary endpoint was the mortality rate. The secondary endpoints were duration of intensive-care unit management, invasive mechanical ventilation, and hospital stay. The inverse probability weighting method with estimated propensity scores was used to minimize the data collection bias. We included 3519 patients with influenza pneumonia with respiratory failure. Of these, 875 were treated with corticosteroids. There was no significant difference between the groups regarding 30-day and 90-day mortality, duration of intensive-care unit management, invasive mechanical ventilation, and hospital stay. However, the in-hospital mortality rate was higher in the corticosteroid group. The use of systematic corticosteroid therapy in patients with influenza pneumonia was associated with a higher in-hospital mortality rate.

Keywords: ARDS; infection and inflammation; influenza; viral infection.
 
Back
Top Bottom